Risk of Secondary Cancers After CART-cell Therapy Low
Stanford Cancer Institute
A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR T-cell therapy is low, despite a U.S. Food and Drug Adm…































